Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 48 |
| Active Pipeline (Recruiting Now) | 25 (15) |
| Completed vs Stopped Early | 1 / 0 (0.0%) |
| Median Closed Actual Enrollment | 200 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| West China Hospital of Sichuan University | Chengdu, Sichuan | 16 |
| West China Hospital,Sichuan University | Chengdu, Sichuan | 13 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06121505 | Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamo | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Sichuan University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.